Atrandi Biosciences
6 known investors
Atrandi builds single-cell analysis technology based on Semi-Permeable Capsules (SPCs) and droplet platforms, enabling multi-step, multi-omic workflows to be run on the same cell. It serves research laboratories working on applications such as co-sequencing, microbial genomics, and single-cell screening workflows.
BiotechDeep TechHardware
Investors · 6
GRIDS CapitalSão Paulo
MetaplanetTallinn · $500K – $10M
Practica CapitalVilnius · $324K – $3.2M
Vsquared VenturesMünchen
Lux Capitalreported · 2 sourcesNew York · $100K – $100M
Also in the syndicate · 1
CRIDS Capital
Funding
SEC filings, press & company announcements$25M disclosed across 1 round · 2025
- $25MSeries AFeb 2025 · 3 sources
Lux Capital (lead), CRIDS Capital, GRIDS Capital, Metaplanet, Practica Capital, Vsquared Ventures
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Atrandi Biosciences do?
- Atrandi builds single-cell analysis technology based on Semi-Permeable Capsules (SPCs) and droplet platforms, enabling multi-step, multi-omic workflows to be run on the same cell. It serves research laboratories working on applications such as co-sequencing, microbial genomics, and single-cell screening workflows.
- Who are Atrandi Biosciences's investors?
- Atrandi Biosciences's investors include GRIDS Capital, Metaplanet, Practica Capital, Vsquared Ventures, Lux Capital.
- How much funding has Atrandi Biosciences raised?
- Atrandi Biosciences has disclosed $25M raised across 1 round.